The FDA approved scPharmaceuticals’ supplemental New Drug Application for FUROSCIX, expanding its use to treat edema in adults with chronic kidney disease (CKD), including nephrotic syndrome. FUROSCIX, a subcutaneous furosemide injection, is already indicated for edema in chronic heart failure patients and is expected to be available for CKD patients in April 2025. This approval broadens FUROSCIX’s applicability within the cardiorenal space.
This approval is particularly important for CKD patients, who frequently experience fluid overload, a serious complication that can lead to hospitalization. FUROSCIX offers a convenient at-home treatment option, potentially reducing hospital readmissions and improving patient quality of life. This subcutaneous delivery method is a significant advantage over intravenous administration, typically requiring a hospital setting. The expansion of the FUROSCIX indication addresses a significant unmet need in CKD management, offering nephrologists an important new tool.
FUROSCIX is now indicated for treating edema in adults with chronic heart failure or CKD, including nephrotic syndrome. While generally well-tolerated, potential side effects include fluid and electrolyte imbalances, dehydration, and injection site reactions. Careful monitoring of patients, especially the elderly and those with pre-existing conditions, is essential.
This expanded indication strengthens scPharmaceutical’s position in the cardiorenal market. It creates new revenue opportunities and solidifies FUROSCIX as a key player in managing fluid overload across a broader patient population. The anticipated availability in April 2025 allows time for the company to finalize commercial launch plans and engage with nephrologists to drive adoption of FUROSCIX for this new patient group.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
